临床研究显示，使用SSTR2激动剂的PET显像在脑膜瘤中表现出高准确性和与SSTR2表达的相关性。然而，[68 Ga]Ga-DOTA-JR11与SSTR2拮抗剂的实用性尚不确定。为评估[68 Ga]Ga-DOTA-JR11 PET/CT的诊断性能，并澄清疑似脑膜瘤患者的肿瘤特征，本前瞻性研究于2021年8月至2022年10月招募了复杂部位或非典型影像的可疑新发或复发脑膜瘤患者。所有患者均接受增强MRI（CE-MRI）、[68 Ga]Ga-DOTA-JR11 PET/CT和组织病理学评估。通过SUVmax和肿瘤颅内比（TBR）来测量[68 Ga]Ga-DOTA-JR11的肿瘤摄取量。 PET和MRI之间进行诊断性能比较。 共有36名患者（年龄50.0±13.0岁，其中20名女性），其中32名患者经组织病理学确认为脑膜瘤，另外4名患者为其他肿瘤。脑膜瘤患者[68 Ga]Ga-DOTA-JR11的摄取量显著高于其他肿瘤（SUVmax：13.6±7.7 vs. 5.2±3.0，P<0.001；TBR：64.2±27.7 vs. 25.0±18.9，P=0.001）。[68 Ga]Ga-DOTA-JR11 PET/CT检测到31个脑膜瘤，而CE-MRI仅检测到25个初诊病例中的17个脑膜瘤和11个复发肿瘤；相对于MRI，[68 Ga]Ga-DOTA-JR11 PET在初诊病例中具有24%（6/25）的增量诊断价值。对于所有36名患者，PET和MRI的诊断有效性之间没有统计学上的显著差异（P=0.45）。对于基底颅膜瘤，PET可更准确地诊断垂体受累（12例中有12例，8例中有8例），相对于MRI（6例中有8例，6例中可能有6例，6例中可能没有4例）。PET显示所有14名通过病理证实存在骨受累的患者，而MRI仅鉴别出11例。 [68 Ga]Ga-DOTA-JR11 PET/CT具有高质量的图像和理想的诊断表现，可用于检测脑膜瘤并评估其对垂体和骨的受累情况。该研究提供了[68 Ga]Ga-DOTA-JR11 PET/CT作为对CE-MRI在脑膜瘤评估中的补充成像模态的有价值证据。 © 2023. 本文作者(们)独家许可给施普林格出版公司德国分公司，属施普林格自然出版集团。

Clinical studies of PET imaging using SSTR2 agonists have demonstrated high accuracy and correlation with SSTR2 expression in meningiomas. However, the usefulness of the SSTR2 antagonist with [68 Ga]Ga-DOTA-JR11 is uncertain. To evaluate the diagnostic performance of [68 Ga]Ga-DOTA-JR11 PET/CT and to clarify tumor characteristics in patients with suspected meningiomas.Patients with suspected de novo or recurrent meningioma in complex locations or atypical images were enrolled from August 2021 to October 2022 in prospective study. All patients underwent contrast-enhanced MRI (CE-MRI), [68 Ga]Ga-DOTA-JR11 PET/CT, and histopathological evaluation. Tumor uptake of [68 Ga]Ga-DOTA-JR11 was measured by SUVmax and tumor-endocranium ratio (TBR). Diagnostic performance was compared between PET and MRI.Of 36 (50.0 ± 13.0 years of age, 20 women) patients, 32 were histopathologically confirmed meningiomas and four with other tumors. [68 Ga]Ga-DOTA-JR11 uptake was significantly higher in meningioma patients than in those with other tumors (SUVmax: 13.6 ± 7.7 vs. 5.2 ± 3.0, P < 0.001; TBR: 64.2 ± 27.7 vs. 25.0 ± 18.9, P = 0.001). [68 Ga]Ga-DOTA-JR11 PET/CT detected 31 meningiomas, while CE-MRI detected 17 meningiomas of 25 initial diagnosis and 11 recurrent tumors; [68 Ga]Ga-DOTA-JR11 PET had an incremental diagnostic value of 24% (6/25) over MRI in the group of initial diagnosis. There was no statistically significant difference in diagnostic efficacy between PET and MRI (P = 0.45) for all 36 patients. In skull base meningiomas, PET provided a more definitive diagnosis of pituitary involvement (in 12, not in12), compared to MRI (in eight, possible in six, possible not in six, not in four). PET revealed bone involvement in all 14 patients proven by pathology, while MRI identified only 11.[68 Ga]Ga-DOTA-JR11 PET/CT provided high image quality and presented an ideal diagnostic performance in detecting meningioma and evaluating the involvement of the pituitary and bone. The study provides valuable evidence for the use of [68 Ga]Ga-DOTA-JR11 PET/CT as a complementary imaging modality to CE-MRI in the evaluation of meningiomas.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.